FORBELI s.r.o.

The trials here

What the 19 trials at this site are about, from their registry records.

Conditions

• Alzheimer disease11 trials
• Migraine4 trials
• Epilepsy2 trials
• ALS (motor neurone disease)1 trial
• Parkinson disease1 trial

Phase

• Phase 39 trials
• Phase 28 trials
• Phase 1/21 trial
• Phase 2/31 trial

Status

• Completed13 trials
• Recruiting3 trials
• Active, not recruiting2 trials
• Suspended1 trial

Lead sponsor

• AbbVie4 trials
• ACADIA Pharmaceuticals Inc.2 trials
• AriBio Co., Ltd.1 trial
• Bristol-Myers Squibb1 trial
• Cognition Therapeutics1 trial
• and 10 more

Running trials

• Recruiting

  A Study to Assess Safety and Tolerability and to Explore Efficacy of NSC001 in Mild to Moderate Alzheimer's Disease

  NCT06995573· Phase 1/2· NSC-Therapeutics· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

  NCT06976216· Phase 3· Bristol-Myers Squibb· Source

• Active, not recruiting

  A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine

  NCT06602479· Phase 2· AbbVie· Source

• Enrolling by invitation

  ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study

  NCT06194799· Phase 3· ACADIA Pharmaceuticals Inc.· Source

• Active, not recruiting

  Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)

  NCT05531526· Phase 3· AriBio Co., Ltd.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Alzheimer disease3 recruiting

Closed trials

• Completed

  A clinical trial to learn about the effects of VHB937 in people with Alzheimer's disease

  2024-516966-12-00· Phase 2· Novartis Pharma AG· Source

• Recruiting

  Efficacy and Safety Study of Once-Daily Extended-Release Levetiracetam in Drug-resistant Focal Onset Seizures

  2024-514499-42-00· Phase 3· Neuraxpharm Pharmaceuticals S.L.· Source

• Completed

  A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments

  NCT06323928· Phase 2· H. Lundbeck A/S· Source

• Completed

  Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine

  NCT06241313· Phase 3· AbbVie· Source

• Completed

  Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD)

  NCT06182085· Phase 2· PRInnovation GmbH· Source

• Completed

  Randomised, double-blind, placebo-controlled study to assess safety and efficacy of PRI-002 in patients with MCI or mild dementia due to Alzheimer’s disease (AD)

  2022-503148-41-00· Phase 2· Prinnovation GmbH· Source

• Recruiting

  ACP-204 in Adults With Alzheimer's Disease Psychosis

  NCT06159673· Phase 2/3· ACADIA Pharmaceuticals Inc.· Source

• Completed

  A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy, Safety, Tolerability, PK, and Biomarker Effects of PTC857 in Adult Subjects With Amyotrophic Lateral Sclerosis (CARDINALS)

  NCT05349721· Phase 2· PTC Therapeutics Inc.· Source

• Completed

  A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures

  NCT05614063· Phase 3· Xenon Pharmaceuticals Inc.· Source

• Completed

  A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation

  NCT05318976· Phase 2· Inmune Bio, Inc.· Source

• Completed

  Open-label Trial in Parkinson's Disease (PD)

  NCT04760769· Phase 3· AbbVie· Source

• Completed

  A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine

  NCT04686136· Phase 3· AbbVie· Source

• Completed

  A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.

  NCT03507790· Phase 2· Cognition Therapeutics· Source